网站检索

药明生物子公司药明海德与全球疫苗巨头成功签订疫苗长期生产供应合同

时间:2020-02-25 10:32来源:药明生物 点击:0
药明生物子公司药明海德与全球疫苗
巨头成功签订疫苗长期生产供应合同
WuXi Biologics' Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader
(*Please scroll down for English news.)
中国,上海
2020年2月18日
 
全球领先的开放式生物制药技术平台公司药明生物(WuXi Biologics, 2269.HK)今日宣布,其从事疫苗合同定制研发生产(CDMO)服务的子公司药明海德已经与一家全球疫苗巨头达成战略合作伙伴关系,签署了长达二十年的疫苗生产供应合同,将在爱尔兰新建一座疫苗专用生产基地服务全球市场,该合同总金额约30亿美元。
根据该合同,药明海德已经着手在爱尔兰新建一座集疫苗原液、制剂、工艺放大、质量控制(QC)实验室于一体的工业化生产及供应基地,专门生产该客户的创新性疫苗以供应全球市场。该生产基地预计2022年投入运行。
 
2019年11月,药明海德宣布投资2.4亿美元建设疫苗原液及制剂厂等生产基地。该基地将位于药明生物爱尔兰园区内,毗邻药明生物正在建设的全球领先生物制药“未来工厂”生产基地,后者预计将于2021年投入商业化生产。
 
药明海德是药明生物与位于上海的海利生物(股票代码:603718.SH)共同成立的合资企业,致力于打造全球疫苗行业领先的一体化能力和技术平台,提供疫苗合同定制研发生产(CDMO)服务,赋能全球疫苗行业研发和生产。
药明生物子公司药明海德与全球疫苗巨头成功签订疫苗长期生产供应合同
 
“此项战略合作开创了疫苗行业全新合作模式,对药明生物、药明海德乃至全球疫苗产业而言都具有历史性意义。由于生产工艺高度复杂、分析检测方法繁多以及法规标准严格,疫苗生产难度颇高,生产过程中的工艺质量控制对确保产品质量也至关重要。此次与全球疫苗巨头达成战略合作伙伴关系,独家生产一款创新性疫苗并供应全球市场,进一步彰显了药明生物、药明海德领先的技术优势和全球高标准质量体系。”药明生物首席执行官兼药明海德董事长陈智胜博士表示,“疫苗CDMO业务是药明生物发展的新增长点之一,该项目的启动将推动疫苗业务进一步助力公司持续高速增长。药明生物将携手药明海德继续通过健全强大的全球供应链网络,赋能合作伙伴生产高质量治疗性蛋白药物及疫苗产品,造福全球病患,保护人类健康。”
 
关于药明生物
 
 
药明生物(股票代码:2269.HK)作为一家香港上市公司,是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务,帮助任何人、任何公司发现、开发及生产生物药,实现从概念到商业化生产的全过程,加速全球生物药研发进程,降低研发成本,造福病患。截至2019年6月30日,在药明生物平台上研发的综合项目达224个,包括106个处于临床前研究阶段,102个在临床早期(I期,II期)阶段,15个在后期临床(III期)以及1个在商业化生产阶段。预计到2022年,公司在中国、爱尔兰、新加坡、美国规划的生物制药生产基地合计产能将超过28万升,这将有力确保公司通过健全强大的全球供应链网络为客户提供符合全球质量标准的生物药。
如需更多信息,请访问:www.wuxibiologics.com.cn。
 
 
WuXi Biologics’ Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader
 
SHANGHAI, China, 
Feb 18, 2020
 
 
WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing,announced that WuXi Vaccines, its joint venture with Shanghai Hile Bio-technology(603718.SH), has entered into a strategic partnership with a global vaccine leader and signed a 20-year vaccine manufacturing contract valued approximately $3 billion USD, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial vaccine products for the global market.
 
 
Per the contract signed, WuXi Vaccines will build an integrated vaccine manufacturing facility including drug substance manufacturing (DS), drug product manufacturing (DP), Manufacture Science and Technology Labs (MS&T) as well as Quality Control labs (QC). The facility will be dedicated to manufacture one of its partner’s vaccine products for the global market. The new facility is expected to be operational in 2022.
 
 
In Nov 2019, WuXi Vaccines announced 240 million USD investment to build the new vaccine manufacturing facility in Ireland. The facility is located within the WuXi Biologics Campus adjacent to the “Factory of the Future” biologics drug substance manufacturing facility which is scheduled for commercial manufacturing in 2021.
 
 
WuXi Vaccines is a joint venture company established between WuXi Biologics and Shanghai Hile Bio-technology (stock code: 603718.SH). The business model of WuXi Vaccines is to build world-class integrated platforms and CDMO model to enable global companies to develop and manufacture vaccines.
 
 
“This is a historic moment for WuXi Biologics and WuXi Vaccines as well as for the global vaccine industry. Due to process complexity, extensive analytic testing and rigorous regulatory standards, vaccines are difficult to manufacture and process and quality control are extremely critical for the quality of the product. This partnership with a global vaccine leader to exclusively manufacture a vaccine for the global market, first of its kind in the industry, is a further testimony to the technical strengths and premier quality demonstrated by WuXi Vaccines,” commented Dr. Chris Chen, CEO of WuXi Biologics and Chairman of WuXi Vaccines,“Vaccine CDMO is one of the next growth areas for WuXi Biologics. Once this project is initiated, our vaccine business will contribute substantially to the growth of WuXi Biologics. WuXi Biologics together with WuXi Vaccines will continue to provide our global partners with a robust and premier-quality supply chain network to produce high quality biologic and vaccine products to benefit patients worldwide and to protect human being globally, initially with therapeutic proteins and now with vaccines.”
 
About WuXi Biologics
 
 
 
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of June 30, 2019, there were a total of 224 integrated projects, including 106 projects in pre-clinical development stage, 102 projects in early-phase (phase I and II) clinical development, 15 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, Singapore, and the U.S. exceeding 280,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
来源:药明生物
 

(责任编辑:薛海湘)
关于我们 | 联系我们 | 版权声明 | 隐私保护 | 法律责任
  • 版权所有:江苏省外商投资企业协会 Copyright ©2019 jswqxh.org.cn All Rights Reserved
  • 协会地址:南京市中华路50号国贸大厦29楼 邮编:210001 传真:025-52327323 邮箱:js_wzxh@163.com
  • 网站备案/许可证号: 苏ICP备14010449号-1 苏公网安备:32010402000614号

  • 扫一扫关注我